What is GeneDx Holdings's R&D?

GeneDx Holdings (WGS) reported R&D of $19.8M in Q1 2026.

How has GeneDx Holdings's R&D changed year-over-year?

GeneDx Holdings's R&D increased by 57.5% year-over-year, from $12.58M to $19.8M.

What is the long-term trend for GeneDx Holdings's R&D?

Over 4 years (2021 to 2025), GeneDx Holdings's R&D has grown at a -9.0% compound annual growth rate (CAGR), from $105.16M to $72.03M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

GeneDx Holdings WGS R&D

R&D at other companies

Natera, Inc.NTRA

$210.7M+63.2%

Tempus AI, Inc.TEM

$48.24M+34.5%

Bio-Rad LaboratoriesBIO

$62.9M-14.4%

RevvityRVTY

$57.89M+8.0%

IlluminaILMN

$240M-4.8%

Agilent TechnologiesA

$126M+12.5%

Other financials

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

See full

Market cap$1.89B-24.3%

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's R&D?: GeneDx Holdings (WGS) reported R&D of $19.8M in Q1 2026.
How has GeneDx Holdings's R&D changed year-over-year?: GeneDx Holdings's R&D increased by 57.5% year-over-year, from $12.58M to $19.8M.
What is the long-term trend for GeneDx Holdings's R&D?: Over 4 years (2021 to 2025), GeneDx Holdings's R&D has grown at a -9.0% compound annual growth rate (CAGR), from $105.16M to $72.03M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.